FINWIRES · TerminalLIVE
FINWIRES

Piper Sandler Upgrades Tvardi Therapeutics to Overweight From Neutral, Adjusts Price Target to $13 From $3

By

Tvardi Therapeutics Inc. (TVRD) has an average rating of overweight and mean price target of $9.75, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles

Research

Goldman Sachs Lifts Salik PT, Maintains Buy Rating

Goldman Sachs on Wednesday raised the price target for Dubai-based tollgate operator Salik (DFM:SALIK) to 7 Emirati dirhams from 6.80 dirhams, while maintaining its buy rating.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

DFM:SALIK
Research

Citi Downgrades Lufthansa to Sell, Raises PT

Citi on Wednesday downgraded German airline company Deutsche Lufthansa (LHA.F) to sell from neutral and increased its price target to 8.70 euros from 8.20 euros.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$LHA.F
Research

Arqaam Capital Lowers Dubai Islamic Bank's PT, Keeps at Buy

Arqaam Capital on Tuesday reduced the price target for Emirati lender Dubai Islamic Bank (DFM:DIB) to 8.50 Emirati dirhams from 8.70 dirhams and affirmed its buy rating.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

DFM:DIB